In order to further validate the hypothesis, the expansion of Yang Ping's "New Plan" was launched under ethical green lights in multiple countries. As the number of volunteers increased, the first adverse reaction was reported.
The patient was a forty-two-year-old Swedish male Lynch Syndrome carrier, identified as P-009. Seventy-two hours after receiving the first infusion of a personalized modulator, at only one-fifth of Alina's initial dose, he developed a high fever, systemic rash, and a sharp increase in liver function indicators. After emergency hospitalization, infection and other drug factors were ruled out, pointing to a serious immune-related adverse reaction.
